OR WAIT null SECS
August 15, 2019
GNA Biosolutions has completed its latest round of Series C financing in which it raised US$13.5 million.
The European Commission has approved an extension of the use of Dupixent (dupilumab) within the EU to include patients aged 12 to 17 years old with moderate-to-severe atopic dermatitis.
Optima Pharma opened a new assembly hall, the CSPE Center, that will give the company space to build complete, multi-story pharmaceutical manufacturing facilities.
August 13, 2019
AskBio’s acquisition of Synpromics will improve the efficacy of its adeno-associated virus gene therapy vectors.
August 12, 2019
The new facility will manufacture biopharmaceutical products under cGMP conditions.
August 02, 2019
Pharmaceutical Technology Europe celebrates 30 years in publishing the latest insights, analysis, and developments of the bio/pharma industry.
European Union regulators have taken a significant step towards resolving some of the major supply-chain difficulties behind medicine shortages.
Much has changed in the bio/pharma industry over three decades. In this special feature, the editors take a trip down memory lane, highlighting some of the major happenings of the past 30 years.
Europe has introduced a waiver for supplementary protection certificates, polarizing opinions throughout the industry. In this interview, the SPC waiver and its implications for European pharma are discussed.
July 31, 2019
Alizé Pharma 3 completed a €67 million Series A financing round led by LSP to boost its product portfolio in rare endocrine and metabolic diseases.